Dr. Richard T. Kloos to Appointed Executive Medical Director of Veracyte

mJOULE Launches in the United Kingdom Reports Sciton

"Sciton is dedicated to worldwide support and growth. We continue to demonstrate our commitment to developing high quality devices and marketing efforts for our physician and medspa partners worldwide." says Lacee J. Naik, Vice President of Marketing and Public Relations.

FDA Issues Draft Guidance on Remanufacturing and Discussion Paper Seeking Feedback on Cybersecurity Servicing of Medical Devices

With this in mind, the FDA is issuing today's draft guidance to help clarify whether activities performed on medical devices are likely remanufacturing as well as a discussion paper on cybersecurity servicing of devices.

Irrimax Receives FDA Clearance for Irrisept

"This new clearance from the FDA further solidifies Irrisept as the market leader in wound irrigation," said Mark Alvarez, CEO of Irrimax.

September 14, 2020

Dr. Richard T. Kloos has been appointed Executive Medical Director of Veracyte. The news was announced today.

Dr. Richard Kloos joined Veracyte in 2012. He was previously a professor in the divisions of Endocrinology and Metabolism, and Nuclear Medicine at The Ohio State University (OSU) and was attending physician at The OSU Comprehensive Cancer Center. He was co-director of The OSU Thyroid Cancer Unit and served for a four-year term as secretary and chief operating officer for the American Thyroid Association (ATA). His contributions to medicine include more than 200 peer-reviewed publications, books chapters, and scientific abstracts. He served on ATA and National Comprehensive Cancer Network task forces that published standard-setting guidelines for thyroid nodules and thyroid cancer.

“We are thrilled to promote Rick to this important new role as we grow our offerings that inform diagnosis and treatment decisions throughout the patient journey in a range of cancers and in lung disease,” said Dr. Kennedy. “Rick has been instrumental in the success of our Afirma testing, which is creating a new standard of care for patients undergoing evaluation for thyroid cancer. We believe his medical expertise and leadership will be especially important as we introduce four new clinical products next year, including our first-of-its-kind, non-invasive nasal swab test for earlier lung cancer diagnosis and our Percepta® Atlas to help inform lung cancer targeted therapy selection.”

“I believe Veracyte, with its remarkable culture, talent, and rigorous approach to genomic science and technology, is at the forefront of helping patients realize the benefits of precision medicine in cancer and other diseases,” said Dr. Kloos. “I’m excited to guide our work with the medical community as we continue to deliver genomic tests that transform patient care in the United States and in global markets.”

 

 

spot_img

DON'T MISS

Hyperfine Adds Medtech Leader and Visionary Scott Huennekens as Executive Chairman

Mr. Huennekens’ public boards include Chairman of Acutus Medical (IPO August 2020); Chairman of Envista (IPO September 2019); and board member of Nuvasive. He also serves as a board member and past Chairman of the Medical Device Manufacturer’s Association (MDMA).

One Drop Reports Carrie Siragusa, CPA Appointed VP of Commercial Strategy, Biosensor

Formerly Head of Innovation and Diabetes Portfolio at Sanofi, Siragusa will be part of a team bringing a multi-analyte dermal sensor (biosensor) with continuous health sensing capabilities to market with a mission to provide broader access to continuous glucose monitoring.

Barbara Moorhouse Appointed as Medica Non-Executive Director

Barbara has extensive business and management experience in the private, public, and regulated sectors.

Subscribe to Medical Device News Magazine here.

Related Articles

Join our list

Subscribe to our mailing list and receive an end-of-week recap news and updates delivered right to your email inbox.